What is Zacks Research’s Forecast for WST Q2 Earnings?

West Pharmaceutical Services, Inc. (NYSE:WST) – Analysts at Zacks Research raised their Q2 2025 EPS estimates for West Pharmaceutical Services in a research report issued to clients and investors on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $1.50 per share for the quarter, up from their previous forecast of $1.44. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q3 2025 earnings at $1.61 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.93 EPS and Q1 2027 earnings at $1.44 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.23. The company had revenue of $698.00 million during the quarter, compared to analysts’ expectations of $685.24 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. West Pharmaceutical Services’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.56 earnings per share.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Stephens raised shares of West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, April 21st. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research report on Friday, February 14th. Evercore ISI assumed coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 price objective for the company. Finally, KeyCorp cut their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $332.50.

West Pharmaceutical Services Trading Up 1.8%

Shares of West Pharmaceutical Services stock opened at $210.46 on Friday. The firm has a 50-day moving average of $215.20 and a 200-day moving average of $275.77. The stock has a market cap of $15.12 billion, a PE ratio of 31.46, a PEG ratio of 6.74 and a beta of 1.14. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $357.85. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently added to or reduced their stakes in the stock. Unisphere Establishment boosted its position in West Pharmaceutical Services by 49.0% in the first quarter. Unisphere Establishment now owns 29,500 shares of the medical instruments supplier’s stock valued at $6,604,000 after buying an additional 9,700 shares in the last quarter. LGL Partners LLC lifted its stake in shares of West Pharmaceutical Services by 59.1% in the 1st quarter. LGL Partners LLC now owns 1,036 shares of the medical instruments supplier’s stock valued at $232,000 after acquiring an additional 385 shares during the last quarter. Durable Capital Partners LP lifted its stake in shares of West Pharmaceutical Services by 146.8% in the 1st quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock valued at $352,190,000 after acquiring an additional 935,721 shares during the last quarter. Quarry LP bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $27,000. Finally, Nomura Holdings Inc. lifted its stake in shares of West Pharmaceutical Services by 111.3% in the 1st quarter. Nomura Holdings Inc. now owns 5,034 shares of the medical instruments supplier’s stock valued at $1,127,000 after acquiring an additional 2,652 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, July 30th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.40%. West Pharmaceutical Services’s payout ratio is currently 13.19%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.